The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Musculocutaneous and muscle flaps contain a layer of muscle to provide bulk that can fill a deeper defect. If skin cover is needed, a skin graft can be placed over top of it. Examples include gastrocnemius flaps, latissimus dorsi flaps, TRAM flaps, and transverse upper gracillis flaps. Bone flaps contain bone and are used when structural support is needed, such as in jaw reconstruction or fibula flaps. Omental flaps can be used in chest wall defects, and intestinal flaps can be used to reconstruct tubular structures like the esophagus.
==== Partially competitive ==== The mechanism of partially competitive inhibition is similar to that of non-competitive, except that the EIS complex has catalytic activity, which may be lower or even higher (partially competitive activation) than that of the enzyme–substrate (ES) complex. This inhibition typically displays a lower Vmax, but an unaffected Km value.
17α-OHP is the parent compound of a class of progestins referred to as the 17α-hydroxyprogesterone derivatives. Among others, this class of drugs includes chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate.
DNA was first isolated by the Swiss physician Friedrich Miescher who, in 1869, discovered a microscopic substance in the pus of discarded surgical bandages. As it resided in the nuclei of cells, he called it "nuclein". In 1878, Albrecht Kossel isolated the non-protein component of "nuclein", nucleic acid, and later isolated its five primary nucleobases. In 1909, Phoebus Levene identified the base, sugar, and phosphate nucleotide unit of RNA (then named "yeast nucleic acid"). In 1929, Levene identified deoxyribose sugar in "thymus nucleic acid" (DNA). Levene suggested that DNA consisted of a string of four nucleotide units linked together through the phosphate groups ("Tetranucleotide hypothesis"). Levene thought the chain was short and the bases repeated in a fixed order. In 1927, Nikolai Koltsov proposed that inherited traits would be inherited via a "giant hereditary molecule" made up of "two mirror strands that would replicate in a semi-conservative fashion using each strand as a template". In 1928, Frederick Griffith in his experiment discovered that traits of the "smooth" form of Pneumococcus could be transferred to the "rough" form of the same bacteria by mixing killed "smooth" bacteria with the live "rough" form. This system provided the first clear suggestion that DNA carries genetic information. In 1933, while studying virgin sea urchin eggs, Jean Brachet suggested that DNA is found in the cell nucleus and that RNA is present exclusively in the cytoplasm.
Sources: en.wikipedia.org
Sickle cell disorders, which are the most prevalent form of hemoglobinopathy. Sickle hemoglobin (HbS) is prone to polymerize when deoxygenated, precipitating within the red blood cell. This damages the RBC membrane resulting in its premature destruction and consequent anemia. Unstable hemoglobin variants are mutations that cause the hemoglobin molecule to precipitate, spontaneously or upon oxidative stress, resulting in hemolytic anemia. Precipitated, denatured hemoglobin can attach to the inner layer of the plasma membrane of the red blood cell (RBC) forming Heinz bodies, leading to premature destruction of the RBC and anemia. Change in oxygen affinity. High or low oxygen affinity hemoglobin molecules are more likely than normal to adopt the relaxed (R, oxy) state or the tense (T, deoxy) state, respectively. High oxygen affinity variants (R state) cause polycythemia (e.g., Hb Chesapeake, Hb Montefiore). Low oxygen affinity variants can cause cyanosis (e.g., Hb Kansas, Hb Beth Israel).
=== Physiological effects === According to a dose-response study in human subjects, dimethyltryptamine administered intravenously slightly elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-endorphin, corticotropin, cortisol, and prolactin; growth hormone blood levels rose equally in response to all doses of DMT, and melatonin levels were unaffected."
Produced by Frances Berrigan, directed by Christopher Swayne, made by Cicada Films with the Discovery Channel 8 September The Big G, about gravity; Saturn's gravity destroyed its moons, to make its rings; Newton's laws unleashed the industrial revolution; geophysicist Victoria Lagenheim of the USGS, and gravimetry (gravity mapping); physicist Gabriel Luther; astrophysicist Robert Kirshner of the Harvard-Smithsonian Center for Astrophysics; Andrulla Blanchette; Apollo asteroid (35396) 1997 XF11 will approach the Earth on 26 October 2028 at 600,000 miles; reproductive biologist Lynn Maxey Wiley of UC Davis; neurologist Edward Good; neuroscientist Muriel Ross of NASA Ames; astrobiologist James Clifford of NASA Ames; Ralph Pelligra, chief medical officer at NASA Ames; astronauts Bernard A. Harris Jr. and David Wolf (astronaut); the ISS would be complete by 2004; astrophysicist Alex Filippenko at University of California, Berkeley; astrophysicist Saul Perlmutter at Lawrence Berkeley National Laboratory; astrophysicist Adam Riess of the High-Z Supernova Search Team, who found in 1998 that the universe rate of expansion is increasing, winning the 2011 Nobel Prize for Physics.
== Awards and recognition == Eberlin was named among the Forbes "30 Under 30" list in 2015. She won the Marion Milligan Mason Award of the American Association for the Advancement of Science in 2016. The award is given every two years to promising young female researchers in chemistry. She won the MacArthur "Genius" Fellowship from the John D. and Catherine T. MacArthur Foundation in 2018 for her research on the use of mass spectrometry "to differentiate more quickly and accurately diseased from healthy tissues during surgery". She is the first UT Austin professor to win MacArthur grant this century. The award consists of a $625,000 no-strings-attached grant. According to the foundation, this award goes to "extraordinarily talented and creative individuals as an investment in their potential". She also won the Moore Inventor Fellowship in 2018. She received the 2020 Curt Brunnée Award from the International Mass Spectrometry Foundation. She was named on the Power List by the Analytical Scientist in 2014, 2018, 2019, 2021, 2022, 2023, and 2024. She received the 2024 Norman Hackerman Award from the Welch Foundation and the Biemann Medal from the American Society for Mass Spectrometry in 2025.
=== Pharmacokinetics === The drug is orally active, in contrast to the poor oral bioavailability of ketamine. Its oral bioavailability is >60%. The time to peak levels of blixeprodil is 1.5 hours and its elimination half-life is 4.3 hours.
Sources: en.wikipedia.org
Thomas A. Wadden (born September 3, 1952) is an American psychologist who is known for his research on the behavioral, pharmacological, and surgical treatment of obesity. He is Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, where he served as Director of the Center for Weight and Eating Disorders for over two decades. From 2011 to 2021, he held the endowed Albert J. Stunkard Professorship in Psychiatry. Wadden has published more than 500 peer-reviewed scientific papers and edited seven volumes on obesity and eating disorders. He has contributed to national health policy on obesity management, serving on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the United States House of Representatives. He is a fellow of The Obesity Society. In 2015, The Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.
Akinesia A loss or impairment of voluntary movement, often associated with Parkinson's disease and basal ganglia dysfunction. Allodynia A condition in which normally non-painful stimuli are perceived as painful, often due to nerve damage or sensitization. Alpha wave A type of brainwave oscillation in the frequency range of 8–13 Hz, commonly associated with relaxed, wakeful states and measured using electroencephalography (EEG). Alzheimer's disease A progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and the presence of amyloid plaques and neurofibrillary tangles in the brain. Amygdala A brain structure involved in emotion, particularly fear, aggression, and emotional memory formation. It is part of the limbic system. Anencephaly A severe congenital condition in which a major portion of the brain, skull, and scalp is missing due to failed closure of the neural tube. Anhedonia The inability to experience pleasure, commonly associated with depression and certain neurological disorders. Anterograde amnesia A form of memory loss in which new memories cannot be formed following brain injury or trauma; often associated with damage to the hippocampus. Anterior cingulate cortex A region of the cingulate cortex implicated in functions such as emotion regulation, cognitive control, error detection, and decision-making. Aphasia A language disorder resulting from brain damage, most often in the left hemisphere, that affects the production or comprehension of speech and writing.
=== Area associations (Landschaftsverbände) === The most populous state of North Rhine-Westphalia is uniquely divided into two area associations (Landschaftsverbände), one for the Rhineland, and one for Westphalia-Lippe. This arrangement was meant to ease the friction caused by uniting the two culturally different regions into a single state after World War II. The Landschaftsverbände now have very little power. The constitution of Mecklenburg-Vorpommern at §75 states the right of Mecklenburg and Vorpommern to form Landschaftsverbände, although the old border between these two constituent parts of the state is not represented in the current administrative division.
Other, rather rare, skin associated symptoms include pyoderma gangrenosum, Sweet's syndrome, drug reactions, erythema nodosum, lobe panniculitis, atrophy of finger skin, palmar erythema, and skin fragility (often worsened by corticosteroid use). Diffuse alopecia areata (Diffuse AA) occurs more commonly in people with rheumatoid arthritis. RA is also seen more often in those with relatives who have AA.
== Chemistry == Proteins constitute 90-95% of venom's dry weight and are responsible for almost all of its biological effects. The hundreds, even thousands, of proteins found in venom include toxins, neurotoxins in particular, as well as nontoxic proteins (which also have pharmacological properties), and many enzymes, especially hydrolytic ones. Enzymes (molecular weight 13-150 KDa) make up 80-90% of viperid and 25-70% of elapid venoms, including digestive hydrolases, L-amino-acid oxidase, phospholipases, thrombin-like pro-coagulant, and kallikrein-like serine proteases and metalloproteinases (hemorrhagins), which damage vascular endothelium. Polypeptide toxins (molecular weight 5-10 KDa) include cytotoxins, cardiotoxins, and postsynaptic neurotoxins (such as α-bungarotoxin and α-Cobratoxin), which bind to acetylcholine receptors at neuromuscular junctions. Compounds with low molecular weight (up to 1.5 KDa) include metals, peptides, lipids, nucleosides, carbohydrates, amines, and oligopeptides, which inhibit angiotensin-converting enzyme (ACE) and potentiate bradykinin (BPP). Inter- and intra-species variation in venom chemical composition is geographical and ontogenic. Phosphodiesterases interfere with the prey's cardiac system, mainly to lower the blood pressure. Phospholipase A2 causes hemolysis by lysing the phospholipid cell membranes of red blood cells. Amino acid oxidases and proteases are used for digestion. Amino acid oxidase also triggers some other enzymes and is responsible for the yellow colour of the venom of some species.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.